Brainstorm Cell Therapeutics reported $2.05M in Operating Expenses for its fiscal quarter ending in March of 2026.





Operating Expenses Change Date
Alterity Therapeutics Limited AUD 8.67M 893.38K Dec/2025
Biogen USD 2.32B 663.6M Sep/2026
Brainstorm Cell Therapeutics USD 2.05M 198K Mar/2026
Cipla INR 63.61B 1.3B Sep/2026
Clal Biotechnology ILS 5.15M 9.47M Dec/2022
Compugen USD 11.44M 246K Jun/2026
CSL USD 5.7B 2.82B Dec/2025
Cytokinetics USD 214.64M 6.85M Sep/2026
Gilead Sciences USD 13.04B 9.09B Sep/2026
Grifols EUR 1.99B 217.4M Dec/2025
Halozyme Therapeutics USD 198M 4.66M Sep/2026
Mesoblast USD 88.91M 6.6M Jun/2026